Currently, the Alpine drug is set to enter a Phase 3 clinical trial by the end of the year and studies of its application in renal indications and autoimmune cytopenias are ongoing.
CG Life buys Toolhouse to brand itself as ‘science-first, tech-enabled’ firm
Following closure of the deal, Shockwave will operate as a business unit within J&J MedTech and its financials will be reported into the parent’s cardiovascular portfolio.